A 54-year-old patient finally brings it up at the end of a hormone therapy follow-up visit, after we have already covered every other concern she came in with. Sex hurts. It has hurt for two years. She has stopped initiating, her marriage has gotten quieter around it, and she has not mentioned it to anyone — not to her gynecologist, not to her primary care physician, and almost not to me. When I ask why she had not raised it sooner, she shrugs and says she figured it was just part of getting older and there was nothing to do about it.
That is the conversation that frustrates me most in this work, because she is wrong on both counts. It is not just part of getting older — it is a specific, treatable condition called genitourinary syndrome of menopause (GSM), and there is a tiered set of effective treatments, several of which I prescribe regularly. The reason this gets missed is that nobody is asking the question, including a lot of clinicians who should be. I will ask it directly, and the patients who come in for sexual wellness conversations leave with an actual plan rather than a shrug.
What GSM actually is — the physiology behind the symptoms
Vaginal atrophy is the older clinical term. The current preferred term is genitourinary syndrome of menopause because the condition affects more than the vagina — it involves the vulva, the urethra, the bladder trigone, and the surrounding pelvic tissue, all of which are estrogen-dependent and all of which thin and dysfunction in parallel as estrogen declines.
The mechanism is straightforward. The vaginal epithelium and the urogenital tissues have a high density of estrogen receptors. Estrogen maintains the thickness of the epithelial layer, supports the population of glycogen-storing superficial cells that feed lactobacilli (which keep vaginal pH acidic and protective), preserves blood flow and elasticity, and maintains the moisture-producing capacity of the surrounding glands.
When estrogen drops in menopause — or in surgical menopause, or in patients on aromatase inhibitors for breast cancer — the epithelium thins from 8 to 10 cell layers down to 2 to 3. Glycogen production drops. Lactobacilli populations crash. Vaginal pH rises from around 4.0 to above 5.5. Blood flow decreases. The tissue becomes pale, friable, and fragile. The patient experiences this as dryness, burning, dyspareunia (painful intercourse), urinary urgency, recurrent UTIs, and sometimes spotting after intercourse from microabrasion of the thinned tissue.
The progression is typically slow and silent. Most women do not notice the early changes; by the time symptoms are bad enough to bring it up, the tissue change has been underway for years. Roughly 50 to 70 percent of postmenopausal women have GSM symptoms; fewer than 25 percent ever discuss them with a clinician.
The hormonal treatments — what works and how I think about delivery
When the underlying mechanism is estrogen deficiency, the most effective treatment restores estrogen to the affected tissue. The decision is how — local versus systemic, and which vehicle.
Local vaginal estrogen is my first-line treatment for isolated GSM in patients who do not need systemic hormone therapy for other indications. The options:
- *Vaginal estradiol cream* (Estrace) — applied with an applicator, typically nightly for two weeks then twice weekly maintenance. Inexpensive, effective, but somewhat messy.
- *Vaginal estradiol tablets* (Vagifem, Yuvafem) — small inserts, twice weekly after a loading phase. Cleaner application, well-tolerated, generally my preferred option for patients who want something simple.
- *Vaginal estradiol ring* (Estring) — a flexible silicone ring inserted every 90 days, releasing estradiol locally. Excellent for patients who do not want to think about it twice a week.
The systemic absorption from properly dosed local vaginal estrogen is minimal. Serum estradiol levels remain within the postmenopausal range. This is one of the safest hormone interventions in medicine, including in most patients with a personal history of breast cancer (current ASCO and NAMS guidance allows it after consultation with the patient's oncologist for hormone-receptor-positive disease).
Vaginal DHEA (prasterone, prescribed as Intrarosa) is an alternative for patients who prefer not to use local estrogen directly. DHEA is converted intracellularly to estrogen and androgen at the tissue level. Effective, well-tolerated, and a useful option in the breast cancer population.
Systemic hormone optimization addresses GSM as part of a broader picture in patients who also have vasomotor symptoms, sleep disruption, mood changes, or bone density concerns. When I prescribe systemic estrogen for these indications, vaginal symptoms generally improve as part of the response, though some patients still benefit from adding low-dose local estrogen on top for complete tissue response.
The non-hormonal treatments — what they do and where they fit
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
Not every patient is a candidate for hormonal treatment, and not every patient wants it. The non-hormonal options have a real role.
Vaginal moisturizers (Replens, Hyalo Gyn, Revaree) are not lubricants — they are designed for regular use, two to three times weekly, to maintain tissue hydration between intercourse. They do not reverse epithelial atrophy, but they reduce day-to-day dryness and discomfort meaningfully. I recommend them as adjuncts in almost every GSM patient and as primary therapy in patients who decline hormonal options.
Lubricants for use specifically with intercourse — water-based, silicone-based, or hybrid. Useful but not curative. Silicone-based lubricants tend to be more durable and require less reapplication, but should not be used with silicone toys.
Hyaluronic acid vaginal preparations (Revaree is the most widely available) — bind water in the tissue, modest improvement in epithelial hydration. Reasonable option as a non-hormonal regular use product.
Pelvic floor physical therapy — often overlooked. Many patients with GSM have developed protective pelvic floor hypertonicity from years of painful intercourse, and the muscle tension is itself contributing to the dyspareunia. A skilled pelvic floor PT can be transformative, particularly when paired with tissue-level treatment.
Ospemifene (Osphena) — an oral SERM (selective estrogen receptor modulator) with estrogenic effects on vaginal tissue and minimal systemic estrogenic activity. An option for patients who want a systemic non-hormonal option, though it carries some venous thromboembolism risk and I screen for it.
The O-Shot — a PRP-based regenerative treatment using the patient's own platelet-rich plasma injected into specific anatomical sites in the vulvovaginal region. This is a regenerative rather than replacement intervention; the mechanism is platelet-derived growth factor stimulation of local tissue regeneration. I have seen meaningful improvement in tissue quality, sensation, and symptoms in appropriate candidates, though I am clear with patients that the evidence base is smaller than the evidence base for vaginal estrogen and that response varies. Patients who are not candidates for estrogen — or who want to layer regenerative treatment on top of hormonal treatment — are the population I most often discuss it with.
How I evaluate a patient for GSM
The first sexual wellness consultation in my practice is a real conversation, scheduled with enough time that we are not rushing. I cover symptom history (when did this start, what does it feel like, when does it happen, what makes it worse and better), prior treatments attempted (including over-the-counter products and any prescriptions), full medication review (SSRIs, anticholinergics, antihistamines, and aromatase inhibitors all aggravate GSM), full sexual history including frequency of sexual activity (less frequent activity worsens GSM through reduced tissue blood flow — the "use it or lose it" effect is real and physiological), and the partner picture if relevant.
A pelvic exam is part of the workup when the patient consents. The clinical findings are usually obvious: pale or thinned vaginal mucosa, loss of rugae, decreased elasticity, sometimes pinpoint petechiae from friability, often a narrowed introitus. Vaginal pH testing is a simple objective measure — anything above 5.0 in a non-menstruating woman supports the diagnosis.
Lab work depends on the broader picture. If the patient is also a hormone therapy candidate, I run the comprehensive panel — estradiol, FSH, total and free testosterone, SHBG, thyroid panel, and metabolic markers. If the picture is isolated GSM in a patient already on systemic hormones, the lab work is typically already in hand.
What I look for in a male partner picture
This blog is primarily about GSM in women, but I treat couples regularly and the male side of the equation matters. If a patient's male partner is dealing with erectile dysfunction or low libido, the clinical picture changes — and treating only the woman often fails because the dynamic of the relationship is on both sides. I will offer to evaluate the partner separately for men's hormone therapy or ED treatment if relevant. The conversation is private, the protocols are evidence-based, and the outcomes when both partners are addressed in parallel are meaningfully better than when only one is.
What to do next
If you are dealing with vaginal dryness, painful intercourse, recurrent UTIs, or any of the other symptoms I described above, the next step is a private consultation. I will ask the questions directly that nobody else has asked, examine if the picture warrants it, and walk through which of the hormonal and non-hormonal options actually fit your situation. For most patients, the first-line answer is local vaginal estrogen — which is safe, inexpensive, well-tolerated, and meaningfully effective. For patients in whom that is not the right answer, there is a tiered set of alternatives.
The visit is private. The documentation is handled with the same standards as every other medical record. The consultation room at both the Columbus consultation clinic and the Warner Robins location is set up for these conversations to happen without rush. If GSM has been the symptom you have been quietly tolerating for months or years, the next month is the right time to stop tolerating it.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.